• Profile
Close

Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease

Diabetes, Obesity and Metabolism Jan 27, 2019

Charytan DM, et al. - Given that metformin could have benefits on cardiovascular disease and the progression of kidney disease but is often withheld from people with diabetes and chronic kidney disease (CKD) due to the potential increased risk of lactic acidosis, researchers assessed metformin for safety and cardiovascular events in patients with type 2 diabetes and CKD. Study participants included 591 people who used metformin at baseline and 3,447 non-users. Findings suggested an independent association of metformin use with a reduced risk of all-cause mortality, cardiovascular death, the cardiovascular composite, and the kidney disease composite. Data reported that there were two cases of lactic acidosis. In patients with stage 3 CKD, metformin might be safer for use than previously considered and may lower the risk of death and cardiovascular events.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay